Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet

Publication date: May 2016
Source:European Journal of Cancer, Volume 58
Author(s): Maria A. Pantaleo, Margherita Nannini




from Cancer via ola Kala on Inoreader http://ift.tt/1oOmxjS
via IFTTT